Summary:
A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab monotherapy by subcutaneous injection in participants aged 18 years and older with moderate-to-severe atopic dermatitis.
Qualified Participants Must:
• 18 years or older
•
Clinically diagnosed with Atopic Dermititis
•
Moderate to Severe Eczema
Qualified Participants May Receive:
Possible eczema Relief
No Cost Medicine
Preliminary Assessment at No Cost
Compensation for time and travel - up to $3,000